178 related articles for article (PubMed ID: 37709682)
1. Intrapleural Thrombolytics as First Line Therapy for Complicated Parapneumonic Effusions and Empyema in Patients with Prohibitive Surgical Risk: A Cases Series.
Morales-Colón S; Rivera-Agosto MM; Mercader-Pérez M; Cantres-Contreras O; Rodríguez-Cintrón W
P R Health Sci J; 2023 Sep; 42(3):241-245. PubMed ID: 37709682
[TBL] [Abstract][Full Text] [Related]
2. Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.
Altmann ES; Crossingham I; Wilson S; Davies HR
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684683
[TBL] [Abstract][Full Text] [Related]
3. Predictive Variables for Failure in Administration of Intrapleural Tissue Plasminogen Activator/Deoxyribonuclease in Patients With Complicated Parapneumonic Effusions/Empyema.
Khemasuwan D; Sorensen J; Griffin DC
Chest; 2018 Sep; 154(3):550-556. PubMed ID: 29425674
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Tissue Plasminogen Activator and DNase for Complicated Pleural Effusions Secondary to Abdominal Pathology.
Majid A; Ochoa S; Chatterji S; Fernandez-Bussy S; Kheir F; Rivera E; Cheng G; Folch E
Ann Am Thorac Soc; 2017 Mar; 14(3):342-346. PubMed ID: 28079399
[TBL] [Abstract][Full Text] [Related]
5. Choice of intrapleural fibrinolytic agents in the treatment of adult complicated parapneumonic effusion and empyema: Network meta-analysis.
Yokoyama Y; Kuno T; Takagi H; Burfeind W
Asian Cardiovasc Thorac Ann; 2023 Jun; 31(5):451-458. PubMed ID: 37287257
[TBL] [Abstract][Full Text] [Related]
6. Management of Intrapleural Sepsis with Once Daily Use of Tissue Plasminogen Activator and Deoxyribonuclease.
Mehta HJ; Biswas A; Penley AM; Cope J; Barnes M; Jantz MA
Respiration; 2016; 91(2):101-6. PubMed ID: 26761711
[TBL] [Abstract][Full Text] [Related]
7. Intrapleural tissue plasminogen activator and deoxyribonuclease administered concurrently and once daily for complex parapneumonic pleural effusion and empyema.
Smith D; Shaw H; Ryder T
Intern Med J; 2023 Dec; 53(12):2313-2318. PubMed ID: 37029951
[TBL] [Abstract][Full Text] [Related]
8. Intrapleural therapy in management of complicated parapneumonic effusions and empyema.
Ahmed AH; Yacoub TE
Clin Pharmacol; 2010; 2():213-21. PubMed ID: 22291507
[TBL] [Abstract][Full Text] [Related]
9. Mixing It Up: Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema.
Bishwakarma R; Shah S; Frank L; Zhang W; Sharma G; Nishi SP
J Bronchology Interv Pulmonol; 2017 Jan; 24(1):40-47. PubMed ID: 27984384
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural Thrombolytics for Parapneumonic Effusion: A Network Metaanalysis.
Sridharan K; Sivaramakrishnan G
Curr Rev Clin Exp Pharmacol; 2024; 19(2):204-212. PubMed ID: 36173062
[TBL] [Abstract][Full Text] [Related]
11. Update on the role of intrapleural fibrinolytic therapy in the management of complicated parapneumonic effusions and empyema.
Singh G; Pitoyo CW; Nasir AU; Rumende CM; Amin Z
Acta Med Indones; 2012 Jul; 44(3):258-64. PubMed ID: 22983084
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.
Livingston MH; Mahant S; Connolly B; MacLusky I; Laberge S; Giglia L; Yang C; Roberts A; Shawyer A; Brindle M; Parsons S; Stoian C; Walton JM; Thorpe KE; Chen Y; Zuo F; Mamdani M; Chan C; Loong D; Isaranuwatchai W; Ratjen F; Cohen E
JAMA Pediatr; 2020 Apr; 174(4):332-340. PubMed ID: 32011642
[TBL] [Abstract][Full Text] [Related]
13. Stratifying fibrinolytic dosing in pediatric parapneumonic effusion based on ultrasound grade correlation.
James CA; Braswell LE; Pezeshkmehr AH; Roberson PK; Parks JA; Moore MB
Pediatr Radiol; 2017 Jan; 47(1):89-95. PubMed ID: 27709281
[TBL] [Abstract][Full Text] [Related]
14. Intrapleural Fibrinolytics and Deoxyribonuclease for Treatment of Indwelling Pleural Catheter-Related Pleural Infection: A Multi-Center Observational Study.
Fitzgerald DB; Muruganandan S; Tsim S; Ip H; Asciak R; Walker S; Uribe Becerra JP; Majid A; Ahmed L; Rahman NM; Maskell NA; Blyth KG; Lee YCG
Respiration; 2021; 100(5):452-460. PubMed ID: 33784710
[TBL] [Abstract][Full Text] [Related]
15. Intra-pleural fibrinolytic therapy vs. conservative management in the treatment of parapneumonic effusions and empyema.
Cameron R
Cochrane Database Syst Rev; 2000; (3):CD002312. PubMed ID: 10908554
[TBL] [Abstract][Full Text] [Related]
16. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis.
Tokuda Y; Matsushima D; Stein GH; Miyagi S
Chest; 2006 Mar; 129(3):783-90. PubMed ID: 16537882
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of large-dose intrapleural alteplase for complicated pediatric parapneumonic effusion and empyema.
Taylor JL; Liu M; Hoff DS
J Pediatr Pharmacol Ther; 2015; 20(2):128-37. PubMed ID: 25964730
[TBL] [Abstract][Full Text] [Related]
18. Parapneumonic pleural effusion and empyema.
Koegelenberg CF; Diacon AH; Bolliger CT
Respiration; 2008; 75(3):241-50. PubMed ID: 18367849
[TBL] [Abstract][Full Text] [Related]
19. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema.
Cameron R; Davies HR
Cochrane Database Syst Rev; 2008 Apr; (2):CD002312. PubMed ID: 18425881
[TBL] [Abstract][Full Text] [Related]
20. Comparing the outcomes of intrapleural fibrinolytic and DNase therapy versus intrapleural fibrinolytic or DNase therapy: A systematic review and meta-analysis.
Chong WH; Hu K; Saha BK; Chopra A
Pulm Pharmacol Ther; 2021 Dec; 71():102081. PubMed ID: 34571093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
